INO Inovio Pharmaceuticals, Inc.
Legal ·
Inovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026.
Inovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026.
Inovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share.
Inovio Pharmaceuticals, Inc. develops DNA medicines for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases, along with proprietary electroporation devices used to deliver them. Its product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic. Its most advanced program, INO-3107, is a DNA medicine for adults with RRP. In December 2025 the FDA accepted the company's BLA for INO-3107 for review under the accelerated approval program. The FDA granted a standard 10-month review rather than priority review, with a PDUFA target date of October 30, 2026. The FDA has noted as a potential review issue its preliminary conclusion that the company had not provided adequate information to justify eligibility for accelerated approval, and the FDA has agreed to meet with the company. The company has a small commercial organization and no in-house sales team. Its text also cites collaborations with Chinese companies, agreements with government agencies that may be terminated, and substantial doubt about its ability to continue as a going concern.
| Product or program | What it is | Stage |
|---|---|---|
| INO-3107 | DNA medicine for adults with RRP under accelerated approval review | BLA accepted; PDUFA target date October 30, 2026 |
| CELLECTRA delivery devices | Electroporation devices used to deliver DNA medicines | marketing authorization required |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $54.2 million | $75.6 million |
| Net income (loss) | -$84.9 million | -$107.3 million |
| Cash from operations | -$88.6 million | -$104.1 million |
| Cash and equivalents | $44.3 million | $65.8 million |
| Short-term investments | $14.2 million | $28.3 million |
Our latest story on this, dated Oct 6, 2026: "Inovio faces securities class action and five derivative suits over INO-3107 statements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 12, 2024: "Inovio Pharmaceuticals prices $30 million offering of stock and warrants at $3.00". The story links the filing or release it is based on. Read the story.
Inovio Pharmaceuticals, Inc. trades under the ticker INO on NASDAQ.
Inovio Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:INO; BMV:INO; GETTEX:GBM; LS:A400EJ; LSE:0A43; LSX:A400EJ.
The SEC Central Index Key (CIK) for Inovio Pharmaceuticals, Inc. is 1055726. Its filings are on SEC EDGAR.
103,397,518 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Inovio Pharmaceuticals, Inc. under United States.
Our directory classifies Inovio Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Inovio Pharmaceuticals, Inc. is US45773H4092.
aibio.space lists Inovio Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Inovio Pharmaceuticals, Inc. develops DNA medicines for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases, along with proprietary electroporation devices used to deliver them. Its product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic.
INO-3107: DNA medicine for adults with RRP under accelerated approval review Stage: BLA accepted; PDUFA target date October 30, 2026.
CELLECTRA delivery devices: Electroporation devices used to deliver DNA medicines Stage: marketing authorization required.
Inovio Pharmaceuticals, Inc. reported a net loss of $84.9 million for the fiscal year ended Dec 31, 2025, and used $88.6 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio